Trifecta Capital Advisors LLC Has $2.23 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Trifecta Capital Advisors LLC increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 3,625.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,533 shares of the biopharmaceutical company's stock after purchasing an additional 2,465 shares during the period. Trifecta Capital Advisors LLC's holdings in Regeneron Pharmaceuticals were worth $2,225,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Norges Bank purchased a new position in Regeneron Pharmaceuticals during the fourth quarter valued at $697,296,000. FMR LLC grew its stake in shares of Regeneron Pharmaceuticals by 7.3% in the 3rd quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company's stock worth $8,098,661,000 after buying an additional 669,517 shares in the last quarter. International Assets Investment Management LLC grew its stake in shares of Regeneron Pharmaceuticals by 76,169.5% in the 4th quarter. International Assets Investment Management LLC now owns 591,089 shares of the biopharmaceutical company's stock worth $519,148,000 after buying an additional 590,314 shares in the last quarter. Moneta Group Investment Advisors LLC grew its stake in shares of Regeneron Pharmaceuticals by 57,848.7% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 582,384 shares of the biopharmaceutical company's stock worth $420,184,000 after buying an additional 581,379 shares in the last quarter. Finally, Assenagon Asset Management S.A. grew its stake in shares of Regeneron Pharmaceuticals by 129.3% in the 4th quarter. Assenagon Asset Management S.A. now owns 216,523 shares of the biopharmaceutical company's stock worth $190,170,000 after buying an additional 122,103 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have commented on REGN. StockNews.com cut shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Friday, January 5th. Royal Bank of Canada raised their target price on shares of Regeneron Pharmaceuticals from $1,096.00 to $1,184.00 and gave the stock an "outperform" rating in a report on Tuesday, February 27th. Cantor Fitzgerald raised their target price on shares of Regeneron Pharmaceuticals from $850.00 to $925.00 and gave the stock a "neutral" rating in a report on Tuesday, February 6th. Barclays raised their target price on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an "overweight" rating in a report on Tuesday, January 23rd. Finally, BMO Capital Markets raised their target price on shares of Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an "outperform" rating in a report on Monday, February 5th. Four research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $968.43.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock traded down $4.22 during midday trading on Monday, reaching $938.48. The company's stock had a trading volume of 330,916 shares, compared to its average volume of 491,826. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $684.80 and a fifty-two week high of $998.33. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 5.69. The stock's 50 day simple moving average is $959.92 and its 200 day simple moving average is $886.01. The firm has a market capitalization of $103.01 billion, a PE ratio of 27.13, a P/E/G ratio of 2.75 and a beta of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, beating analysts' consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The company had revenue of $3.43 billion during the quarter, compared to the consensus estimate of $3.29 billion. During the same quarter last year, the company earned $10.96 earnings per share. Regeneron Pharmaceuticals's quarterly revenue was up .6% compared to the same quarter last year. On average, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 38.18 earnings per share for the current year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Andrew J. Murphy sold 5,783 shares of the firm's stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the sale, the executive vice president now owns 48,306 shares of the company's stock, valued at $46,203,239.82. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, EVP Andrew J. Murphy sold 5,783 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the transaction, the executive vice president now owns 48,306 shares of the company's stock, valued at approximately $46,203,239.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, March 1st. The stock was sold at an average price of $982.05, for a total value of $98,205.00. Following the transaction, the director now directly owns 18,282 shares of the company's stock, valued at approximately $17,953,838.10. The disclosure for this sale can be found here. Over the last quarter, insiders sold 13,729 shares of company stock valued at $13,124,641. 8.83% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.